Comprehensive Analysis of the Massachusetts Alternative Simplified Credit (ASC) under M.G.L. c. 63, § 38M(b)

The Alternative Simplified Credit (ASC) under M.G.L. c. 63, § 38M(b) allows Massachusetts corporations to calculate their R&D tax credit as 10% of current-year research expenses exceeding 50% of their previous three-year average.1 This method provides a streamlined computational path that utilizes a rolling historical lookback period, thereby reducing the administrative burden associated with the traditional fixed-base ratio calculation.3 The implementation of the ASC represents a significant shift in the Commonwealth’s tax policy, moving toward a model that rewards consistent and growing investment in innovation rather than tethering incentives to historical gross receipts from the 1980s.3 By decoupling the credit from the complex federal “regular method” and its reliance on ancient financial data, Massachusetts has effectively lowered the barrier to entry for both startups and established firms that have undergone significant structural changes.3 The ASC serves as a vital component of the broader Massachusetts Research and Development tax credit framework, which is designed to maintain the state’s competitive edge as a global hub for life sciences, technology, and advanced manufacturing.4 This report explores the statutory underpinnings, regulatory guidance, and operational nuances of the ASC, providing a technical roadmap for tax practitioners and corporate decision-makers seeking to optimize their innovation-related incentives in the Commonwealth.4

Statutory Evolution and the Framework of M.G.L. c. 63, § 38M

The Massachusetts research credit is fundamentally established under M.G.L. c. 63, § 38M, which grants a credit against the corporate excise tax for qualifying expenses incurred during research activities conducted within the state.1 While the credit has been a staple of the Massachusetts tax code for decades, the modern landscape was reshaped by the “Act Promoting Economic Growth Across the Commonwealth,” signed into law in 2014.2 This legislation introduced subsection (b), which codified the Alternative Simplified Method (ASM) or Alternative Simplified Credit (ASC) as an elective alternative to the traditional incremental credit found in subsection (a).1

The statutory text of § 38M(b) defines the credit as a percentage of the excess of qualified research expenses (QREs) over a base amount calculated from the three immediately preceding taxable years.1 A critical feature of the statute is the phased-in rate increase, which began in 2015 and reached its permanent 10% level in 2021.1 This phased approach allowed the Commonwealth to manage the fiscal impact of the transition while signaling a long-term commitment to a more accessible credit structure.6

In the event that a corporation lacks a three-year history of research expenses, the statute provides a protective “fallback” rate.1 If a corporation did not have qualified research expenses in any one of the three preceding taxable years, the credit is fixed at 5% of the total qualified research expenses for the current year.1 This ensures that new market entrants and early-stage startups are not excluded from the incentive simply due to a lack of longevity in their research programs.6

Adoption of Federal Definitions and Intent

The Massachusetts legislature intended for the § 38M credit to closely parallel the federal research credit available under Internal Revenue Code (IRC) § 41.4 Consequently, the statute dictates that terms such as “qualified research expenses,” “basic research payment,” and “credit year” shall, unless context requires otherwise, have the same meanings as they do under the IRC as amended and in effect on specific dates—generally January 1, 2014, for the simplified method.1 However, the state deviates from federal law in several key areas, most notably the requirement that the research must be physically conducted within the borders of Massachusetts.4 This geographic nexus ensures that the tax expenditure directly supports the local economy and labor market.7

Analysis of Massachusetts Department of Revenue (DOR) Guidance

The interpretation and application of M.G.L. c. 63, § 38M(b) are governed by several key pieces of guidance issued by the Department of Revenue.2 These documents provide the “bright-line” rules necessary for compliance and help practitioners navigate the complexities of combined reporting, short tax years, and aggregated group calculations.6

Technical Information Releases: TIR 14-13 and TIR 14-16

Technical Information Release (TIR) 14-13 served as the inaugural guidance for the 2014 reforms, explaining the mechanics of the two elective calculation methods.5 The DOR clarified that for tax years beginning on or after January 1, 2015, a business corporation could choose between the revised traditional method and the new alternative simplified method.5 The TIR highlighted that the traditional method (Option 1) was itself revised to simplify the definition of the “fixed-base ratio” to a rolling lookback, but it remained fundamentally different from the ASC (Option 2) in its reliance on gross receipts.5

Following TIR 14-13, the Department issued TIR 14-16 to provide technical corrections necessitated by the Supplemental Budget (St. 2014, c. 359).2 These corrections were vital because they solidified the phased-in rates and clarified that the 5% fallback rate applies specifically when a corporation is missing data for any of the three prior years.2 This TIR also emphasized that the Commissioner of Revenue has the authority to provide electronic notices to taxpayers, a move aimed at modernization and operational efficiency in tax administration.2

Regulatory Depth in 830 CMR 63.38M.2

The regulation 830 CMR 63.38M.2 provides the most detailed procedural requirements for calculating the credit.6 It explicitly limits the credit to business corporations subject to tax under M.G.L. c. 63, § 39, and clarifies the treatment of S-corporations.6 While S-corporations are eligible for the credit against their corporate excise (under either the income or non-income measure), they are strictly prohibited from sharing any excess credit with their shareholders.6 This distinguishes the Massachusetts R&D credit from its federal counterpart, which typically flows through to individual investors.16

Furthermore, 830 CMR 63.38M.2(8) details the “Inadequate Records” rule.6 If a corporation has a history of expenses in the prior three years but lacks the accounts or records necessary to verify those expenses, it is barred from using the ASC.6 In such cases, the taxpayer is forced to use the traditional method under 830 CMR 63.38M.2(4), which may result in a significantly less advantageous credit if the default fixed-base ratio is applied.3

Interaction with Net Income Deductions

A critical compliance point addressed in the regulatory guidance is the “add-back” or deduction reduction required by M.G.L. c. 63, § 30.4.6 To prevent a double tax benefit, the deduction for research expenses otherwise allowable for the credit year must be reduced by the amount of the credit determined under § 38M(a) or (b).6 This adjustment is made on Schedule E (for Form 355 or 355S) or Schedule U-E (for combined filers), ensuring that the tax benefit of the credit is partially offset by the loss of the expense deduction at the state level.12

Computational Mechanics of the Alternative Simplified Method

The Alternative Simplified Method is designed to reward incremental growth in research spending relative to a taxpayer’s recent history.4 The calculation removes the volatility associated with gross receipts, focusing entirely on the trend of qualified research expenses.3

Calculation Formula for Established Entities

For a corporation that has incurred qualified research expenses in each of the three taxable years preceding the credit year, the credit is determined using the following formula 1:

1. Calculate the 3-Year Average: Sum the QREs for the three preceding taxable years and divide by three.
2. Determine the Base Amount: Multiply the 3-year average by 50% (0.50).
3. Identify Incremental Expenses: Subtract the base amount from the current year’s QREs. If the result is negative, the credit generated for the current year is zero.
4. Apply the Applicable Rate: Multiply the incremental expenses by the statutory rate (10% for years beginning on or after January 1, 2021).

Mathematically, the credit is expressed as:

$$Credit = 0.10 \times \left( QRE_{CY} – \left( 0.50 \times \frac{QRE_{PY1} + QRE_{PY2} + QRE_{PY3}}{3} \right) \right)$$

.1

The 5% Fallback Methodology

If a corporation does not have QREs in each of the three preceding years, the calculation shifts to a flat percentage of total current-year spend.1 This is common for startups or businesses relocating their R&D operations to Massachusetts.3 In these instances, the credit is simply:

$$Credit = 0.05 \times QRE_{CY}$$

.1

This “deemed base” approach eliminates the need for complex historical reconstructions during a company’s early years.3 It is important to note that once a corporation has established a three-year history, it must transition to the standard incremental calculation unless it elects to return to the traditional method under subsection (a).12

Aggregated Group Calculations

Under § 38M and 830 CMR 63.38M.2(9), corporations under common control are treated as a single entity for credit calculation purposes.1 This “unified computation” requires the group to aggregate all QREs of all members, eliminating any inter-company transactions that might otherwise inflate research costs.6

The total group credit is then allocated to the individual members based on their proportionate share of the group’s total QREs.6 This allocation is critical for businesses filing a combined return (Form 355U), as each member must separately report its share of the credit on its own Schedule CMS.12

Defining Qualified Research Expenses (QREs) in the Commonwealth

The foundation of any research credit claim, including the ASC, is the proper identification of qualified research expenses.4 Massachusetts largely adopts the federal “four-part test” to determine if an activity qualifies as research.15

The Four-Part Test for Eligibility

To be considered qualified research, an activity must meet four stringent criteria derived from IRC § 41 10:

1. Permitted Purpose: The research must be intended to create a new or improved business component, focusing on performance, reliability, quality, or durability.10
2. Elimination of Uncertainty: The activity must seek to discover information that would eliminate uncertainty regarding the capability, method, or design for developing the business component.10
3. Process of Experimentation: Substantially all of the activities must constitute a process of experimentation, involving the evaluation of alternatives through modeling, simulation, or systematic trial and error.10
4. Technological in Nature: The research must fundamentally rely on the principles of physical sciences, biological sciences, engineering, or computer science.15

Categories of Eligible In-State Expenses

Once an activity is deemed qualified, the associated costs must be categorized.4 Only expenses physically incurred in Massachusetts are eligible.4

• Wages: Payments made to employees for direct research, direct supervision of research, or direct support of research.13 This includes the research portion of a developer’s or scientist’s salary, substantiated by time tracking or reasonable allocation.4
• Supplies: Costs for tangible property, other than land and depreciable property, that is consumed in the research process.13 This often includes chemical reagents, prototype materials, and laboratory supplies.13
• Contract Research: 65% of the amounts paid to third parties for research conducted in Massachusetts on the taxpayer’s behalf.13 The taxpayer must retain the economic risk and the substantial rights to the results of the research.10
• Computer Rental/Time: Sums paid for the use of computers (often cloud computing or server time) used for qualified research conducted within the Commonwealth.9

Tax Liability Limitations and Carryforward Mechanics

The Massachusetts research credit is a nonrefundable incentive (with certain exceptions for life sciences) and is subject to statutory caps that dictate how much credit can be utilized in any given tax year.4

The Excise Utilization Thresholds

A corporation’s ability to use the § 38M credit is restricted by two primary hurdles 12:

1. The $25,000 Bracket: The credit can offset 100% of the corporation’s first $25,000 of excise tax liability.12
2. The 75% Limitation: For any excise liability exceeding $25,000, the credit is limited to offsetting only 75% of that excess.12
3. The Minimum Excise Floor: Under no circumstances can the credit reduce the corporate excise below the statutory minimum tax, which is currently $456.3

For aggregated groups, the $25,000 threshold is shared among the members based on the ratio of each member’s separately determined excise to the total group excise.12 This ensures that large corporate groups do not unfairly multiply the $25,000 bracket through multiple subsidiaries.12

Strategic Carryforward Rules

Because these limitations often result in “trapped” credits, Massachusetts provides robust carryforward provisions that vary depending on why the credit was restricted.4

The indefinite carryforward for credits disallowed by the 75% rule is an exceptionally powerful feature for mature companies with significant R&D spend relative to their Massachusetts taxable income.4 It ensures that the tax incentive remains a viable long-term asset on the balance sheet, even during years of high capital investment or fluctuating profitability.4

The ASC in the Context of the Life Sciences Ecosystem

Massachusetts is a global leader in the life sciences sector, and the R&D tax credit is a primary driver of this leadership.4 For life sciences companies, the ASC takes on additional strategic dimensions, particularly concerning refundability and interaction with other programs.7

Refundability for Certified Life Sciences Companies

Under the Life Sciences Tax Incentive Program, companies certified by the Massachusetts Life Sciences Center (MLSC) can access a unique refund option for their § 38M research credits.7 Certified companies can apply to have their unused research credits refunded at 90% of their value.7

This program is highly competitive and requires an annual application process, usually opening in February and closing by June.21 To qualify, the company must be certified as a life science company and be authorized to take the credit under M.G.L. c. 63, § 38W, which mirrors § 38M but includes specific sector mandates.7 This refundability is a lifeline for pre-revenue biotech firms that incur massive R&D costs but have no current income tax liability to offset.7

Integration with FDA and Orphan Drug Incentives

Life sciences companies frequently stack the § 38M credit with other state-level incentives, such as the FDA User Fee Credit (a 100% credit for drug approval fees) and the Deduction for Qualified Orphan Drug Expenses.7 The ASC calculation remains the preferred choice for these firms because their research spend is often volatile during clinical trial phases, making the 50% of 3-year average base much easier to clear than the traditional method’s gross receipts-based threshold.4

Economic Impact and Innovation Statistics

The efficacy of the Alternative Simplified Credit is reflected in the broader economic data of the Commonwealth.23 Massachusetts consistently attracts more research investment relative to the size of its economy than any other state in the nation.23

R&D Investment Trends

According to the 2023 Index of the Massachusetts Innovation Economy, research investment into Massachusetts has grown by more than 56% since 2015, the year the ASC was first implemented.23 In 2021, the Commonwealth recorded $44.9 billion in research investment, placing it behind only California and New York in total volume, but first in intensity (investment as a percentage of GDP).23

These statistics suggest that the simplification of the R&D credit through the ASC has contributed to a fiscal environment where innovation can thrive.7 The high rate of research investment growth (56% since 2015) suggests that the “rolling lookback” of the ASC incentivizes companies to not only maintain but aggressively increase their R&D footprints within the state.23

Sectoral Contributions

The impact is not limited to biotech. The Innovation Economy accounts for nearly 40% of all jobs in Massachusetts.23 Sectors such as software development, engineering, advanced manufacturing, and chemical production are significant users of the § 38M credit.20 These industries rely on the ASC’s simplified compliance to free up capital that can be reinvested in hiring technical talent, which the state produces at the highest rate per capita in the country.21

Detailed Example: ASC Calculation and Application

To provide practical clarity, we consider the case of “Commonwealth Quantum Dynamics” (CQD), a mid-sized hardware manufacturer based in Lowell, MA.

Scenario Background for CQD

CQD has been conducting research on superconducting materials for several years. In 2024, they increased their investment significantly. They file as a stand-alone corporation.

• Current Year (2024) QREs: $4,500,000
• Prior Year 1 (2023) QREs: $3,800,000
• Prior Year 2 (2022) QREs: $3,200,000
• Prior Year 3 (2021) QREs: $2,600,000
• 2024 Corporate Excise Liability: $250,000

Step 1: Establish the Three-Year Average

The sum of the prior three years is:

$$\$3,800,000 + \$3,200,000 + \$2,600,000 = \$9,600,000$$

The average is:

$$\$9,600,000 \div 3 = \$3,200,000$$

.12

Step 2: Determine the Base Amount (50% rule)

The ASC base is 50% of the average:

$$\$3,200,000 \times 0.50 = \$1,600,000$$

.12

Step 3: Calculate the Incremental Credit

CQD’s incremental QREs are:

$$\$4,500,000 (Current) – \$1,600,000 (Base) = \$2,900,000$$

Applying the 10% rate for 2024:

$$\$2,900,000 \times 0.10 = \$290,000 \text{ (Total Generated Credit)}$$

.1

Step 4: Apply Utilization Limitations

CQD’s tax liability is $250,000. The allowable use is:

1. First $25,000: 100% allowed = $25,000.13
2. Excess Liability: $\$250,000 – \$25,000 = \$225,000$.12
3. 75% of Excess: $\$225,000 \times 0.75 = \$168,750$.13
4. Total Current Year Capacity: $\$25,000 + \$168,750 = \$193,750$.12

Step 5: Final Tax Result and Carryforward

• Total Generated Credit: $290,000
• Credit Used in 2024: $193,750
• Net Excise Due: $\$250,000 – \$193,750 = \$56,250$.13
• Unused Credit to Carry Forward: $\$290,000 – \$193,750 = \$96,250$.4

Because the entire $96,250 of unused credit was prevented from being used by the 75% rule (and the insufficient liability thereafter), this portion can be carried forward indefinitely.4 If CQD had only generated $150,000 in credit, they would have used $150,000 and paid $100,000 in tax.13

Administrative Compliance: Schedule RC and Filing Procedures

To claim the ASC, a corporation must complete and file Schedule RC (Research Credit) with its annual corporate excise return.10

Navigating Schedule RC

Schedule RC requires the taxpayer to make an explicit election at the beginning of the form.8

• Box 2 Checkbox: To elect the ASC, the taxpayer must check the second box in the header, indicating an election under M.G.L. c. 63, § 38M(b).8
• Box 3 Checkbox: Taxpayers may also elect to use Massachusetts gross receipts for related calculations by checking the third box.8
• Part 1 (QREs): This section captures the current year’s qualified wages, supplies, and contract research.12
• Part 2 (ASC Calculation): If the ASC is elected, the taxpayer completes Lines 7 through 13 and skips the traditional method lines (14-22).12

Electronic Filing and Record-Keeping

As detailed in TIR 14-16, the DOR permits and increasingly requires electronic filing for large corporate returns.2 Corporations must maintain a robust audit trail, including contemporaneous documentation of research activities.4 This includes 10:

• Technical Narratives: Documents explaining the scientific or technological goals of each project.
• Project Accounting: Clear links between GL expense accounts and research projects.
• Personnel Records: Documentation of job descriptions and time allocations for employees involved in research.

In the event of a merger or acquisition, the surviving corporation must aggregate the Massachusetts QREs of the absorbed entities for the three-year lookback period.6 This ensures that the “base” correctly reflects the historical research intensity of the newly combined business unit.6

Comparative Perspective: Massachusetts vs. Other States and Federal

Understanding the ASC’s value requires placing it within the national context.25 While Massachusetts offers a highly competitive 10% rate, the rules for calculation and refundability vary significantly across state lines.25

The Massachusetts ASC is notably more generous than Maryland’s basic tier and more modern than California’s system, which lacks an ASC option entirely.25 The indefinite carryforward for credits limited by the 75% rule in Massachusetts is a standout feature that provides long-term corporate value comparable to California’s indefinite carryforward but with a much simpler calculation path.4

Federal Alignment and Deviations

The federal ASC rate under IRC § 41(c)(5) is currently 14%, which is higher than the Massachusetts 10% rate.17 However, the federal credit can often be used to offset payroll taxes for certain small businesses—a feature Massachusetts does not currently offer.17 Conversely, the Massachusetts credit covers the corporate excise tax, which includes both income and non-income (tangible property/net worth) measures, providing a broader base for utilization than a simple income tax credit.3

Audit Risks and Strategic Defense

While the ASC simplifies the math, it does not reduce the scrutiny of the DOR during an audit.4 The “process of experimentation” remains the most common point of contention.10

Common Audit Pitfalls

1. Contractor Nexus: Taxpayers often fail to prove that 100% of the contracted work was performed within Massachusetts.4 If a vendor uses out-of-state subcontractors, those costs must be carved out.13
2. Qualified vs. Non-Qualified Support: Direct support (e.g., a lab technician cleaning equipment) is qualified, but general administrative support (e.g., HR or accounting) is not.17
3. Inadequate Lookback Data: For the ASC, the DOR will often verify the QREs for the three prior years to ensure the base wasn’t artificially deflated to increase the current year’s incremental credit.6

Proactive Audit Defense

To minimize risk, practitioners should conduct annual “R&D Studies”.10 These studies should involve interviewing lead engineers and scientists to document the “uncertainty” and “experimentation” involved in each project contemporaneously.10 Retaining prototypes, test logs, and version control records from software development is essential for proving the technological nature of the work.10

Conclusion: The Strategic Importance of the ASC for the Future

The Alternative Simplified Credit under M.G.L. c. 63, § 38M(b) has proven to be an essential instrument for the Commonwealth’s innovation-led economic strategy.4 By providing a computational path that is both simpler to navigate and responsive to current growth trends, Massachusetts has effectively lowered the cost of capital for firms engaged in high-risk, high-reward research.3

The ASC’s 10% rate, coupled with the indefinite carryforward provisions and sector-specific refundability for life sciences, ensures that the Commonwealth remains a premier destination for global research investment.4 As industries like quantum computing, AI, and gene therapy continue to evolve, the rolling lookback mechanism of the ASC will remain particularly advantageous, rewarding companies for sustained and escalating investments in the technological frontier.3 For the professional practitioner, a nuanced understanding of the DOR’s guidance in TIR 14-16 and 830 CMR 63.38M.2 is not just a matter of compliance, but a fundamental requirement for optimizing the financial performance and competitive positioning of any Massachusetts-based enterprise.2

R&D Tax Credit Preparation Services

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.

If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.

R&D Tax Credit Audit Advisory Services

creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.

Our Fees

Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/